KRAS and pancreatic ductal adenocarcinoma: Here, CXCL1 overexpression in human pancreatic ductal adenocarcinoma (PDAC) was identified using transcriptomic analysis of KRAS-TP53 co-mutated versus KRAS-altered/TP53WT PDAC cell lines, as KRAS-TP53 co-alteration was associated with worse survival in patients with advanced PDAC.